Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD22 chimeric antigen receptor T cell therapy - Kecellitics Biotech

Next Previous
Drug Profile

Anti-CD22 chimeric antigen receptor T cell therapy - Kecellitics Biotech

Alternative Names: Anti-CD22 CAR-T cell therapy - Kecellitics Biotech; Anti-CD22-CAR; CD22 CAR T-cells; CD22 Chimeric Antigen Receptor T-cells

Latest Information Update: 28 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kecellitics Biotech
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in China (Parenteral, Infusion)
  • 14 Nov 2019 Kecellitics Biotech and Hebei Yanda plans the phase I/II trial for Precursor B-cell lymphoblastic leukaemia-lymphoma, Chronic lymphoblastic leukaemia and Non-Hodgkin's lymphoma (In children, In adults, In elderly, Second-line therapy or greater) (Parenteral) in December 2019 (NCT04163575)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top